Biotech Values

[mcbio]

Any beneficiaries from PGNX's misfortune? IRWD's linaclotide has a pdufa for chronic constipation (not OIC) in september. I assumed NKTR would see a small jump but both NKTR and IRWD have gone down today.

THRX is another name that could benefit though I think the question still remains if the issues affecting Relistor are specific to the drug or do they extend to the other drugs targeting OIC as well?